Draft:Alex Zhavoronkov

From Wikipedia, the free encyclopedia
  • Robbins, Tony; Diamandis, Peter H.; Hariri, Robert (2022). Life Force. Simon and Schuster. p. 556-57. ISBN 978-1982121709.[1]
  • Smith, Wesley J. (February 8, 2023). "Harvesting Clones to Live Forever Would Be Monstrous". National Review. (criticizing Zhavoronkov's speculation regarding cloning human bodies for parts)[2]
  • Field, Hayden (June 29, 2023). "The first fully A.I.-generated drug enters clinical trials in human patients". CNBC.[3]
  • Matsuyama, Kanoko (November 14, 2023). "Race for first drug discovered by AI nears key milestone". The Japan Times.[4]
Alex Zhavoronkov
Born
Riga, Latvia[5][6]
Alma materQueen's University at Kingston
Johns Hopkins University (JHU)[7]
Known forThe Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy
Scientific career
Fieldsaging, regenerative medicine, drug development, artificial intelligence
InstitutionsInsilico Medicine, Biogerontology Research Foundation

New text:[edit]

Alex Zhavoronkov (born Aleksandrs Zavoronkovs)[7] is a Latvian-born scientist and author working in biotechnology, regenerative medicine, and aging economics. He is the founder and CEO of Insilico Medicine,[8][9] and as of 2024, was also the director of the Biogerontology Research Foundation,[10][11] a UK-based think-tank for aging research.

In 2022, Zhavoronkov was an author of one of the first peer-reviewed published papers to formally credit ChatGPT as a coauthor.[12] Zhavoronkov reported that when he asked ChatGPT itself whether it should be named as a coauthor, "it responded with multiple compelling reasons as to why it should not".[12]

Previous text:[edit]

Director of the International Aging Research Portfolio, an open-access repository of biomedical grants.

Early life and education

Born in Latvia,[5][6] Zhavoronkov received two bachelor's degrees from Queen's University,[7] a master's degree in biotechnology from Johns Hopkins University and a PhD in physics and mathematics from Moscow State University.[7] In 2017, he was an adjunct professor at the Moscow Institute of Physics and Technology.[13] As of 2023, he was an adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.[14]

Career

Zhavoronkov is the co-founder and CEO of Insilico Medicine, a Hong Kong-based deep learning company focused on drug discovery[15][16] and biomarker development for aging and aging-associated diseases.[17][18]

AI writer Calum Chace wrote that "[w]ithin the longevity research community, Alex Zhavoronkov is well-known for his relentless focus. He works seven days a week and takes no holidays".[5] In 2022, Zhavoronkov participated in a round of financing for Insilico Medicine that raised $60 million for the venture.[19] Zhavoronkov asserted at the time that the industry was "in 'biotechnology winter' where many companies are running out of cash and are dying", and that his fundraising was positioning the company for a coming "biotech spring".[19] In 2023, Zhavoronkov stated that he had "moved the company's R&D to China to capitalize on 'half a trillion dollars' worth of infrastructure and hundreds of thousands of scientists to enable AI-designed drugs".[11]

Publications[edit]

In November 2017, Zhavoronkov proposed the application of the deep learning techniques and blockchain technology for managing human life data.[20][21][22]

Books
Articles
Patents
  • US patent 8442626B2, Alex Zavoronkov, Mikhail Bakhnyan, "Systems and methods for communicating with a computer using brain activity patterns", issued May 14, 2013 [27]

References[edit]

  1. ^ Robbins, Tony; Diamandis, Peter H.; Hariri, Robert (2022). Life Force. Simon and Schuster. p. 556-57. ISBN 978-1982121709.
  2. ^ Smith, Wesley J. (February 8, 2023). "Harvesting Clones to Live Forever Would Be Monstrous". National Review.
  3. ^ Field, Hayden (June 29, 2023). "The first fully A.I.-generated drug enters clinical trials in human patients". CNBC.
  4. ^ Matsuyama, Kanoko (November 14, 2023). "Race for first drug discovered by AI nears key milestone". The Japan Times.
  5. ^ a b c Chace, Calum (November 9, 2022). "How Insilico Medicine Uses AI To Accelerate Drug Development". Forbes Magazine.
  6. ^ a b Smyth, Jamie (June 26, 2023). "Biotech begins human trials of drug designed by artificial intelligence". Financial Times.
  7. ^ a b c d "Alex Zhavoronkov Aims to Take Over the Drug Development World with AI". Genetic Engineering and Biotechnology News. June 20, 2023.
  8. ^ Eric Smaley (2017). "AI-powered drug discovery captures pharma interest". Nature Biotechnology. 35 (7): 605. doi:10.1038/nbt0717-604. PMID 28700560. S2CID 205269847.
  9. ^ Tan, Dawn; Baker, Jalelah Abu (January 4, 2023). "Big investors pour funds into longevity research, accelerating growth in field". CNA.
  10. ^ "Biogerontology Research Foundation Salutes Staff On Multi-Year Drug Development Agreement". Bioengineer.org. August 14, 2017. Retrieved 28 November 2017.
  11. ^ a b Raiany Romanni, "Want to live to 150? The world needs more humans", The Boston Globe (April 2, 2023), p. K1, K5.
  12. ^ a b Berenbaum, May R. (November 22, 2023). "Welcome, AI overlords?". Proceedings of the National Academy of Sciences of the United States of America (PNAS). Vol. 120, no. 48. doi:10.1073/pnas.2318980120.
  13. ^ "News: Neural network learns to select potential anticancer drugs". MIPT News. February 9, 2017.
  14. ^ "A rather disruptive bunch". Buck Institute for Research on Aging. Retrieved October 6, 2023.
  15. ^ Brazil, Rachel (7 December 2017). "Artificial Intelligence: will it change the way drugs are discovered?". Pharmaceutical Journal, the Journal of the Royal Pharmacological Society.
  16. ^ a b Tom Blackwell, "Cutting-edge science seeks treatment for age", Toronto National Post (February 6, 2021), p. As5.
  17. ^ Thomas, Uduak Grace (March 28, 2014). "GenomeWeb: In Silico Medicine Opens US Office, Prepares to Launch Drug Discovery Software for Aging Research Market" – via www.genomeweb.com.
  18. ^ Gantz, Sarah (February 23, 2017). "Insilico Medicine raises $10 million". The Baltimore Sun.
  19. ^ a b Liao, Rita (June 6, 2022). "Hong Kong's AI drug discovery firm Insilico closes $60M Series D". TechCrunch.
  20. ^ "Skolkovo scientist says AI and blockchain could accelerate biomedical research". old.sk.ru.
  21. ^ "Bitcoin Tech Lets People Reclaim Their Data, Says Medical Startup". Inverse. December 7, 2017.
  22. ^ Haskins, Caroline (December 6, 2017). "This Biotech Company Wants You to Give it Selfies and Blood Tests in Exchange for Cryptocurrency".
  23. ^ Scheffler, Daniel (July 9, 2013). "The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy (review)". Edge Media.
  24. ^ Bloomberg Businessweek, Critic 07.22.2013 pp. 74.
  25. ^ "CBS Radio with Dan Raviv in Washington, DC". September 9, 2013. Event occurs at 1:45–5:20.
  26. ^ "Interview with Aging Expert – Alex Zhavoronkov". Book Tour Radio. August 20, 2013.
  27. ^ Bobrov, P; Frolov, A; Cantor, C; Fedulova, I; Bakhnyan, M; Zhavoronkov, A (2011). "Brain-computer interface based on generation of visual images". PLOS ONE. 6 (6): e20674. Bibcode:2011PLoSO...620674B. doi:10.1371/journal.pone.0020674. PMC 3112189. PMID 21695206.

External links[edit]

Previously deleted text[edit]

Alex Zhavoronkov
BornAugust 17, 1979 (age 38)
Riga, Latvia
Alma materJohns Hopkins University (JHU)
Known forThe Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy
Scientific career
Fieldsaging, regenerative medicine, drug development, artificial inteligence
InstitutionsInsilico Medicine, Biogerontology Research Foundation

Alex Zhavoronkov is a scientist working in biotechnology, regenerative medicine, and aging economics. He is the founder of Insilico Medicine,[1] the director of the Biogerontology Research Foundation,[2] a UK-based think-tank for aging research, and also the director of the International Aging Research Portfolio, an open-access repository of biomedical grants. He is the adjunct professor at the Moscow Institute of Physics and Technology.[3]

Education[edit]

Zhavoronkov earned two bachelor's degrees at Queen's University in computer science and commerce. He has a master's in biotechnology from Johns Hopkins University and a PhD in physics and mathematics from Moscow State University.[4]

Career[edit]

He is the co-founder and CEO of Insilico Medicine, a deep learning company focused on drug discovery[5] and biomarker development for aging and aging-associated diseases located at the Emerging Technology Centers of the Johns Hopkins University.[6][7]

Publications[edit]

Since 2011, Dr. Zhavoronkov authored and co-authored over 108 scientific articles published in refereed journals[8] with over 85 papers referenced in PubMed.[9] Many of the highest-impact research papers focus on the applications of deep learning techniques to drug discovery, biomarker development, and aging research.[10]

In November 2017 together with the collaborators from the BitFury Group he proposed the application of the deep learning techniques and blockchain technology for managing human life data[11], [12], [13],[14] and presented the concept at the Singularity University Exponential Medicine conference in San Diego.[15][16]

Editorial roles and conferences[edit]

Dr. Zhavoronkov is the editor of Aging[17] and associate editor of Frontiers in Genetics of Aging.[18] He co-founded the "Annual Aging Research for Drug Discovery Forum" in Basel, Switzerland in 2014, previously called the International Symposium on Geroprotectors [19] as part of the EMBO/Basel Life.[20]

Books[edit]

  • Zhavoronkov, Alex (2013). The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy. Macmillan. ISBN 978-0230342200.

Patents[edit]

  • US patent 8442626B2, Alex Zavoronkov, Mikhail Bakhnyan, "Systems and methods for communicating with a computer using brain activity patterns", issued May 14, 2013 [28]

References[edit]

  1. ^ Eric Smaley (2017). "AI-powered drug discovery captures pharma interest". Nature Biotechnology. 35 (7): 605. doi:10.1038/nbt0717-604. PMID 28700560. S2CID 205269847.
  2. ^ "Biogerontology Research Foundation Salutes Staff On Multi-Year Drug Development Agreement". Bioengineer.org. 14 August 2017. Retrieved 28 November 2017.
  3. ^ MIPT MIPT News: Neural network learns to select potential anticancer drugs 02.09.2017
  4. ^ Executive Profile of Alexander Zhavoronkov Bloomberg.com
  5. ^ Artificial Intelligence: will it change the way drugs are discovered? Pharmaceutical Journal, The Journal of the Royal Pharmacological Society
  6. ^ GenomeWeb: In Silico Medicine Opens US Office, Prepares to Launch Drug Discovery Software for Aging Research Market by Uduak Grace Thomas, March 28, 2014
  7. ^ Baltimore Sun, Insilico Medicine raises $10 million, by Sarah Gantz, February 23, 2017
  8. ^ Google Scholar by Publication Date Google Scholar by Publication Date
  9. ^ PubMed Bibliography Pubmed
  10. ^ Google Scholar by Citation Google Scholar by Citation
  11. ^ Skolkovo Commentary: Skolkovo scientist says AI and blockchain could accelerate biomedical research
  12. ^ Bitcoin Tech Can Let You Decide Who Buys Your Data, Says Medical Startup
  13. ^ This Biotech Company Wants You to Give it Selfies and Blood Tests in Exchange for Cryptocurrency
  14. ^ []
  15. ^ Alex Zhavoronkov presentation at the Exponential Medicine
  16. ^ Singularity University Hub: AI to Scour a Universe of Molecules for Wonder Drugs
  17. ^ Aging Editorial Board
  18. ^ Frontiers in Genetics of Aging Editorial Board
  19. ^ New Scientist report from the International Symposium on Geroprotectors in Basel
  20. ^ 4th Annual Aging Research & Drug Discovery Forum in Basel, Switzerland
  21. ^ Scheffler, Daniel (July 9, 2013). "The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy (review)".
  22. ^ Bloomberg Business week, Critic 07.22.2013 pp. 74
  23. ^ CBS Radio with Dan Raviv in Washington, DC
  24. ^ Book Tour Radio
  25. ^ Ageless Generation on Maruzen
  26. ^ Ageless Generation in Polish
  27. ^ Ageless Generation in Chinese
  28. ^ Bobrov, P; Frolov, A; Cantor, C; Fedulova, I; Bakhnyan, M; Zhavoronkov, A (2011). "Brain-computer interface based on generation of visual images". PLOS ONE. 6 (6): e20674. Bibcode:2011PLoSO...620674B. doi:10.1371/journal.pone.0020674. PMC 3112189. PMID 21695206.

External links[edit]



Category:Living people Category:Johns Hopkins University alumni Category:Moscow State University alumni Category:Queen's University at Kingston alumni Category:Biogerontologists Category:Russian transhumanists

Retrieved from "https://en.wikipedia.org/w/index.php?title=Draft:Alex_Zhavoronkov&oldid=1212646874"